Organ system dysfunctions are frequent complications of hematopoietic stem cell transplantation (HSCT), including allogeneic or autologous bone marrow transplantation Circulating anticoagulants protein C (PC) and antithrombin III (AT) are markers of, and possibly (BMT), and peripheral blood stem cell transplantation (PBSCT). The occurrence of single organ system dysfuncinvolved in the pathogenesis of, significant organ dysfunction, in patients undergoing autologous peripheral tion in the post-transplant period has been shown to predict for subsequent development of multiple organ dysfunction blood stem cell (PSBC) or autologous bone marrow (BM) transplantation. The effect of the stem cell source, and for death. 1,2 Single and multi-organ dysfunction may be due to the culmination of an uncontrolled inflammatory the use of hematopoietic growth factors (GFs), and the specific preparative regimen on the incidence of organ response to some initial event, mediated by an as yet incompletely understood interplay of cytokines, compsystem dysfunction or on post-transplant levels of circulating anticoagulants has not been well studied. We analement, and the coagulation system. In the setting of acutely ill non-transplant patients, this has been termed the syslyzed 205 patients in an attempt to correlate organ dysfunction and AT and PC deficiencies with these temic inflammatory response syndrome. 3 This syndrome has been well described in patients with trauma or severe transplant-specific factors (78 BMT with GM-CSF after transplant, 95 PBSCT without GM-CSF after transinfection, 3-5 but is only recently been recognized in patients undergoing HSCT.
factors, and others such as stem cell source and use of hem-A variety of preparative regimens were used based on the diagnosis, but 190 of 205 (93%) were prepared with one atopoietic GFs on the incidence of organ system dysfunction or on post-transplant levels of PC and AT have not of six regimens: (1) cyclophosphamide, BCNU, etoposide (CBV; 55 patients); (2) cyclophosphamide and TBI been well studied. We analyzed 205 patients undergoing HSCT in an attempt to correlate organ dysfunction and AT (CY/TBI; 52 patients); (3) cyclophosphamide, thiotepa and hydroxyurea (CTH; 27 patients), (4) BCNU, etoposide, and PC deficiencies with these transplant-specific factors.
cyclophosphamide, hydroxyurea (BECH; 25 patients); (5) BCNU, etoposide, Ara-C, cyclophosphamide (BEAC; 21 patients); and (6) ifosphamide, carboplatinum and etopoMaterials and methods side (ICE; 10 patients). The preparative regimen included total body irradiation in 57 cases (28%).
Patients
Standard post-HSCT practices at UNMC have been preThe study group comprised 205 adult patients (95 males viously reported. 9 Because the adverse events occurring and 110 females) undergoing autologous HSCT at the Uniafter HSCT were postulated to be related to the toxicity of versity of Nebraska Medical Center over a 16 month perthe preparative regimens, the first day of the preparative iod. Characteristics of these patients are summarized in regimen is considered 'day 1' in this report. Patients Table 1 . We first analyzed (1) a cohort of 78 consecutive received total parenteral nutrition from day 1 of the transpatients undergoing BMT, treated with continuous infusion plant course until they recovered from mucositis and were GM-CSF after transplant, and compared them with (2) a able to take nutrition orally. All patients received 10 mg of cohort of 95 consecutive patients undergoing PBSCT, withvitamin K 1 weekly as a supplement to their parenteral out use of GM-CSF after transplant. After initial analysis, nutrition solution beginning on day 1. it became apparent that there were differences in measured parameters between the groups, but whether these differences were due to stem cell source (BM vs PBSC) or use
Adverse events of GM-CSF after transplant was not clear. Therefore, we
Patients were monitored daily during their hospitalization analyzed (3) another cohort of 32 consecutive patients for HSCT for the following adverse clinical events: undergoing PBSCT who were also treated with continuous infusion GM-CSF after transplant. All 110 patients who
(1) Pulmonary dysfunction -defined as the use of supreceived GM-CSF were treated with 250 g/m 2 /day given plemental oxygen. The need for supplemental oxygen as a continuous intravenous infusion, beginning the day was generally defined by the presence of hypoxia (as after stem cell infusion and finishing on the 2nd of 2 conshown by oxygen saturation of less than 90% using secutive days when the absolute neutrophil count exceeded finger oximetry). 500/l. In addition, all 127 patients undergoing PBSC har-(2) Hepatic dysfunction -defined by the presence or vests received hematopoietic growth factor (usually GMabsence of hepatic veno-occlusive disease (VOD). This CSF) to mobilize stem cells prior to and during collections.
was defined by clinical criteria, as a total bilirubin of Patients underwent high-dose therapy and transplantation greater than 1.8 mg/dl, right upper quadrant pain, and for non-Hodgkin lymphoma (106 patients), Hodgkin disa weight gain of at least 5%. ease (48 patients), breast cancer (31 patients), acute lym-(3) Central nervous system (CNS) dysfunction -defined phocytic leukemia (two patients), acute myelogenous leuby evaluation of the patient's mental status. Central kemia (eight patients), chronic myelogenous leukemia (two nervous system dysfunction was graded on a scale from patients) or other diseases (eight patients). The majority of 1 to 5 (lethargy, confusion, delirium, seizure, coma). patients transplanted for breast cancer (68%) received autologous BM, and the majority of patients with non-Hodgkin lymphomas (80%) received autologous PBSC. Patients with HD were evenly divided between autologous BMT Laboratory methods and autologous PBSCT.
Blood samples used for determination of antithrombin and protein C level were drawn through heparin-free central and of protein C anticoagulant activity 65-150%.
Autologous BM 78
For all three groups, PC function and PC antigen did not
Statistical methods higher incidence of pulmonary dysfunction (48 vs 23%, P = 0.009) and CNS dysfunction (44 vs 24%, P = 0.03) than Univariate analysis was performed by the Fisher's exact other regimens. Conversely, the CBV preparative regimen test. Logistic regression analysis was used for multivariate was associated with a lower incidence of pulmonary dysanalysis. A P-value of Ͻ0.05 was considered significant. function (10 vs 32%, P = 0.002) and CNS dysfunction (7 vs 33%, P Ͻ 0.001) than other regimens. Female patients had a higher likelihood of pulmonary dysfunction than male Results patients (32 vs 20%, P = 0.06). However, the significance of this is uncertain, since the more toxic CTH regimen was Patients were analyzed as the three groups defined in the used more often in women than in men (25 vs 0%, methods section: patients undergoing BMT treated with P Ͻ 0.001) for breast cancer, and the less toxic CBV regicontinuous infusion GM-CSF after transplant (BM group); men was used more often in men than in women (33 vs patients undergoing PBSCT, without use of GM-CSF after 21%, P = 0.057), usually for Hodgkin disease. transplant (PBSC-NG group); and patients undergoing
In multivariate analysis, neither disease type (Hodgkin PBSCT treated with continuous infusion GM-CSF after disease vs other, or non-Hodgkin lymphoma vs other) nor transplant (PBSC-G group).
preparative regimen were independently predictive of organ dysfunction. As in the univariate analysis, stem cell source was predictive of pulmonary dysfunction. Patients undergoPredictors for organ system dysfunction ing autologous bone marrow transplantation were at a When patients transplanted with PBSC (groups PBSC-NG higher risk for this dysfunction than either patients and PBSC-G) were compared with patients transplanted undergoing PBSCT with GM-CSF (BM vs PBSC-G, odds with BM, stem cell source predicted for development of ratio 7.1, P = 0.002) or patients undergoing PBSCT without organ system dysfunction. Patients transplanted with PBSC GM-CSF (BM vs PBSC-NG, odds ratio 3.4, P = 0.002). had a lower incidence of pulmonary dysfunction (20 vs 40%, P = 0.006) and liver dysfunction (4 vs 13%, P = 0.05) Predictors for anticoagulant deficiencies than patients receiving autologous BM (group BM). However, as discussed above, whether this difference was due When all patients transplanted with PBSC were considered to stem cell source (PBSC vs BM) or to GM-CSF use was together (independent of GM-CSF use, groups PBSC-NG unclear. When patients undergoing PBSCT without GMand PBSC-G), stem cell source also predicted for develop-CSF (PBSC-NG) were analyzed separately from those ment of anticoagulant deficiency. Patients transplanted with undergoing PBSCT with GM-CSF (PBSC-G), the use of PBSC had a lower incidence of PC deficiency (50 vs 81%, growth factor after transplant did not appear to influence the P Ͻ 0.01), and AT deficiency (20 vs 54%, P Ͻ 0.01), as development of subsequent organ dysfunction. Pulmonary compared with patients undergoing bone marrow transplandysfunction was less likely to occur in both the PBSC-NG tation (group BM). group and the PBSC-G group than in patients in the BM To determine if this difference was due to stem cell group (PBSC-NG vs BM, 20 vs 40%, P = 0.007; PBSC-G source (PBSCT vs BMT) or to GM-CSF use, we then anavs BM, 12.5 vs 40%, P = 0.006. There was no statistically lyzed patients undergoing PBSCT without GM-CSF significant difference between the PBSC-NG and the (PBSC-NG) separately from those undergoing PBSCT with PBSC-G groups (P = 0.43). These data are shown in GM-CSF (PBSC-G). In contrast to the data regarding organ Table 2. dysfunction (above), use of GM-CSF after transplantation Liver dysfunction was also less likely to occur in patients did appear to influence the development of subsequent antireceiving PBSC without GM-CSF (PBSC-NG) than in coagulant deficiency. Patients in group PBSC-NG had a patients undergoing bone marrow transplantation (4 vs lower incidence of anticoagulant deficiency than patients in 13%, P = 0.05). Liver dysfunction appeared less likely to group PBSC-G (PC deficiency 50 vs 78%, P = 0.007; AT occur in patients receiving PBSC with GM-CSF (PBSC-G) deficiency 20 vs 47%, P = 0.005). These data are shown than in patients undergoing bone marrow transplantation (3 in Table 3 . vs 13%), but this was not statistically significant, perhaps
The importance of GM-CSF use became more apparent due to the small sample size in the PBSC-G group.
in the multivariate analysis, where it was the only consistThe CTH preparative regimen was associated with a Table 2 Proportion of patients with organ dysfunction during the post- Table 3 Proportion of patients with decreased AT or PC at any time during the post-transplant course, by stem cell source (univariate analysis) transplant period, by stem cell source (univariate analysis) ently significant variable. Patients undergoing PBSCT with-GM-CSF was consistently protective of PC or AT deficiency. Since patients undergoing autologous BMT out GM-CSF (group PBSC-NG) were at significantly lower risk of deficiency of PC and AT (odds ratio 0.16 and 0.16, consistently received GM-CSF after transplant, use of this growth factor, rather than stem cell source, may have been respectively) when compared with patients undergoing either autologous BMT (group BM) or PBSCT with GMthe major determinant of anticoagulant deficiency in these patients. CSF (group PBSC-G). This suggested that the use of GF after transplantation was the major predictor, since patients
The mechanism for the interaction between hematopoietic growth factor and levels of circulating anticoagulants in BM group received post-transplant GM-CSF. Neither disease type (Hodgkin disease vs other, or non-Hodgkin is not entirely clear. GM-CSF administration is associated with the production of a variety of vasoactive mediators, lymphoma vs other) nor preparative regimen were independently predictive of PC or AT deficiency.
including LTB4, 12 IL-2 13 and TNF, 14 and clinically, is associated with capillary leak syndrome. 15 Increased vascular permeability may lead to extravascular redistribution of these factors. In addition, TNF has a procoagulant effect Discussion on vascular endothelium, 16-18 which could lead to consumption of circulating anticoagulants. In patients undergoing high-dose therapy with hematopoietic stem cell transplantation, occurrence of single organ Anticoagulant deficiency has been reported to be predictive for single organ dysfunction, and an etiologic or persystem dysfunction in the post-transplant period predicts for subsequent development of multiple organ dysfunction missive relationship has been suggested. 2 Other data have similarly suggested an etiologic role, or at least strong temand finally, for death. Development of pulmonary dysfunction predicted for and preceded multi-organ failure in one poral relationship, between anticoagulant deficiency and organ dysfunction, in both the setting of transplantation, 19 report, 2 and hepatic dysfunction (as veno-occlusive disease of the liver) predisposed for multi-organ failure in another. 1 and of severe illness or trauma.
6,7,20 Therefore, whatever predicted for anticoagulant deficiency could also be Though the end organ differed, the conclusion reached is the same: single organ failure may not be a disorder conexpected to predict for organ dysfunction. This was not the case: GF use predicted for anticoagulant deficiency, but firmed to one organ but a manifestation of a more generalized abnormality.
stem cell source predicted for organ dysfunctions. This discrepant result may be attributed to an insufficient number In the current study, the relative importance of various transplant-specific factors on the risk of organ dysfunction of patients in the PBSC-G group to demonstrate a difference in incidence of organ dysfunction dependent on use and the risk of anticoagulant deficiency was investigated. Patients undergoing PBSCT were found to be at less risk of GM-CSF. In summary, transplantation with peripheral blood stem of developing pulmonary or liver dysfunction, than patients undergoing autologous BM transplantation. This was true cells was associated with a lower incidence of organ system dysfunction, and this relationship did not appear to be for both PBSC with GM-CSF and PBSC without GM-CSF groups. The use of GM-CSF had no apparent predictive influenced by use of hematopoietic growth factors after transplantation in the patients studied. Anticoagulant value for this risk. Incidence of dysfunction was not statistically different between PBSC-G and PBSC-NG groups.
deficiency after transplantation, however, was strongly associated with the use of GM-CSF after transplantation. However, because of the small numbers of patients and the consequent low power of these analyses, we are not willing
Since the clinical significance of anticoagulant deficiency has been well shown, 2, 6, 7, 19, 20 further studies examining to dismiss the possibility of an effect of GM-CSF on organ dysfunction. these effects of hematopoietic growth factors appear warranted. The mechanism for the influence of the stem cell source on organ dysfunction in the early post-transplant period is unclear. Transplantation of allogeneic bone marrow cells has been found to be associated with a higher incidence References of organ dysfunction than transplantation with autologous peripheral blood stem cells, 10 autologous BMT as compared with PBSCT, though this did
